EQRx, Inc.
EQRX
2.34USDÂ Market ClosedWatchlist
Market Summary
USD2.34
Market ClosedEQRX Stock Price
View Fullscreen
EQRX RSI Chart
EQRX Valuation
EQRX Price/Sales (Trailing)
EQRX Profitability
EQRX Fundamentals
EQRX Revenue
EQRX Earnings
Price Action
Last 7 days
9.6%
Last 30 days
7.7%
Last 90 days
7.7%
Trailing 12 Months
-56.0%
How does EQRX drawdown profile look like?
EQRX Financial Health
EQRX Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2023 | 40.4M | 52.4M | 60.7M | 0 |
| 2022 | 6.6M | 12.8M | 19.0M | 25.1M |
| 2021 | 181.8K | 266.5K | 351.3K | 436.0K |
| 2020 | 0 | 0 | 0 | 97.0K |
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for EQRX
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
| Nov 09, 2023 | ah equity partners bio ii, l.l.c. | sold | - | - | -5,000,000 | - |
| Nov 09, 2023 | borisy alexis | back to issuer | - | - | -18,810,000 | executive chairman |
| Nov 09, 2023 | abernethy amy | back to issuer | - | - | -200,000 | - |
| Nov 09, 2023 | horning sandra | back to issuer | - | - | -470,250 | - |
| Nov 09, 2023 | conde jorge | back to issuer | - | - | -11,433,700 | - |
| Nov 09, 2023 | conde jorge | back to issuer | - | - | -5,000,000 | - |
| Nov 09, 2023 | conde jorge | back to issuer | - | - | -17,438,500 | - |
| Nov 09, 2023 | conde jorge | back to issuer | - | - | -19,192,000 | - |
| Nov 09, 2023 | nallicheri melanie | back to issuer | - | - | -3,851,150 | chief executive officer |
| Nov 09, 2023 | nallicheri melanie | acquired | 1,385,670 | 2.21 | 626,999 | chief executive officer |
Which funds bought or sold EQRX recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
| Dec 06, 2023 | CITIGROUP INC | reduced | -26.11 | -67,232 | 502,029 | -% |
| Nov 24, 2023 | DEUTSCHE BANK AG\ | added | 26.05 | 268,065 | 799,402 | -% |
| Nov 22, 2023 | Graham Capital Management, L.P. | sold off | -100 | -41,491 | - | -% |
| Nov 21, 2023 | Alpine Global Management, LLC | new | - | 3,332,430 | 3,332,430 | 0.42% |
| Nov 21, 2023 | Walleye Capital LLC | added | 58.12 | -53,322 | 32,233 | -% |
| Nov 17, 2023 | JACOBS LEVY EQUITY MANAGEMENT, INC | sold off | -100 | -5,189,930 | - | -% |
| Nov 15, 2023 | MORGAN STANLEY | reduced | -34.81 | -3,079,550 | 10,796,500 | -% |
| Nov 15, 2023 | SMITH, MOORE & CO. | unchanged | - | 12,600 | 77,700 | 0.01% |
| Nov 15, 2023 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | reduced | -4.94 | 34,488 | 290,796 | -% |
| Nov 15, 2023 | GTS SECURITIES LLC | new | - | 48,869 | 48,869 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of EQRx, Inc.
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Nov 17, 2023 | ah bio fund ii, l.p. | 0.0% | 0 | SC 13D/A | |
| Nov 17, 2023 | arch venture fund x, l.p. | - | 0 | SC 13G/A | |
| Nov 15, 2023 | andreessen horowitz fund i, l.p. | 0.0% | 0 | SC 13D/A | |
| Nov 15, 2023 | casdin capital, llc | 0% | 0 | SC 13D/A | |
| Feb 09, 2023 | vanguard group inc | 5.31% | 25,952,741 | SC 13G | |
| Jan 18, 2023 | softbank group corp | 4.5% | 21,800,000 | SC 13D/A | |
| Nov 29, 2022 | casdin capital, llc | 11.5% | 56,297,042 | SC 13D/A | |
| Feb 14, 2022 | gv 2019, l.p. | 9.69% | 47,252,687 | SC 13G | |
| Feb 14, 2022 | citadel advisors llc | 0.0% | 6 | SC 13G/A | |
| Feb 11, 2022 | arch venture fund x, l.p. | 7.5% | 36,335,375 | SC 13G |
Recent SEC filings of EQRx, Inc.
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Nov 20, 2023 | 15-12G | 15-12G | |
| Nov 17, 2023 | EFFECT | EFFECT | |
| Nov 17, 2023 | EFFECT | EFFECT | |
| Nov 17, 2023 | EFFECT | EFFECT | |
| Nov 17, 2023 | SC 13D/A | 13D - Major Acquisition | |
| Nov 17, 2023 | SC 13G/A | Major Ownership Report | |
| Nov 15, 2023 | SC 13D/A | 13D - Major Acquisition | |
| Nov 15, 2023 | SC 13D/A | 13D - Major Acquisition | |
| Nov 14, 2023 | 4 | Insider Trading | |
| Nov 09, 2023 | 4 | Insider Trading |
Peers (Alternatives to EQRx, Inc.)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
HILS | 31.5B | - | 5.25% | 401813.88% | -3.7K | 218.4K | - | -102.45% |
MRNA | 30.6B | 10.7B | 8.54% | -55.34% | -8.83 | 2.87 | -53.67% | -129.46% |
ALNY | 21.3B | 1.7B | 4.15% | -23.37% | -41.84 | 12.38 | 79.37% | 56.87% |
BMRN | 17.5B | 2.3B | 11.05% | -8.44% | 119.09 | 7.58 | 15.05% | 75.21% |
INCY | 12.3B | 3.6B | 0.84% | -34.33% | 28.84 | 3.4 | 8.35% | -51.49% |
| MID-CAP | ||||||||
APLS | 7.6B | 272.9M | 35.37% | 34.74% | -12.51 | 27.78 | 141.38% | 4.43% |
BBIO | 5.9B | - | 14.36% | 263.35% | -10.02 | 48.33 | 54.84% | -12.96% |
ACAD | 3.6B | 631.9M | -7.32% | 48.57% | -24.01 | 5.65 | 23.54% | 31.53% |
AXSM | 3.3B | 223.4M | 11.28% | -10.13% | -16.47 | 14.87 | - | -26.24% |
ARWR | 2.6B | 240.7M | -10.83% | -25.35% | -12.82 | 10.93 | -1.03% | -16.59% |
| SMALL-CAP | ||||||||
CPRX | 1.5B | 348.4M | 11.36% | -14.92% | 24.33 | 4.33 | 81.69% | -7.29% |
NVAX | 661.3M | 1.0B | -22.00% | -67.89% | -1.2 | 0.63 | -43.15% | 58.48% |
INO | 100.5M | 6.4M | - | -79.23% | -0.61 | 15.6 | -44.11% | 50.48% |
IBIO | 37.6M | - | 376.67% | 112.17% | -0.58 | - | - | -29.23% |
CRBP | 23.7M | - | 25.24% | 3980.68% | -0.5 | - | - | -13.74% |
EQRx, Inc. News
Latest updates
Financials for EQRx, Inc.
Income Statement (Last 12 Months)
| Income Statement (Quarterly) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
| Revenue | 2.6% | 16,485,000 | 16,068,000 | 15,442,000 | 12,668,000 | 8,209,000 | 4,091,000 | 182,000 | 127,667 | 73,333 | 19,000 | 144,000 | - |
| Operating Expenses | 10.6% | 101,548,000 | 91,836,000 | 101,798,000 | 100,730,000 | 90,366,000 | 79,090,000 | 85,691,000 | 94,801,000 | 39,976,000 | 34,639,000 | 26,959,000 | - |
| S&GA Expenses | 9.0% | 23,404,000 | 21,476,000 | 27,277,000 | 29,232,000 | 34,095,000 | 31,792,000 | 32,263,000 | 38,585,000 | 16,176,000 | 13,223,000 | 10,282,000 | - |
| R&D Expenses | -54.7% | 19,729,000 | 43,574,000 | 70,933,000 | 71,498,000 | 56,271,000 | 47,298,000 | 53,428,000 | 56,216,000 | 23,800,000 | 21,416,000 | 16,677,000 | - |
| EBITDA Margin | - | - | - | - | - | - | -226 | -226 | -226 | - | - | - | - |
| EBT Margin | - | - | - | - | - | - | -229 | -229 | -229 | - | - | - | - |
| Net Income | -13.3% | -82,631,000 | -72,956,000 | -82,551,000 | -22,177,000 | -85,092,000 | -82,546,000 | 20,726,000 | 1,233,000 | -39,890,000 | -34,526,000 | -26,817,000 | - |
| Net Income Margin | - | - | - | -6.74 | -6.72 | -11.47 | -11.49 | -181 | -229 | -187 | -387 | - | - |
| Free Cashflow | - | - | - | -85,990,000 | -106,753,000 | -62,118,000 | -65,579,000 | -53,951,000 | -182,835,674 | -447,366 | 23,008,040 | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2021Q1 | 2020Q4 |
| Assets | -5.4% | 1,240 | 1,311 | 1,384 | 1,455 | 1,543 | 1,608 | 1,674 | 1,729 | 554 | 553 | 536 | 518 | 501 |
| Current Assets | -3.8% | 1,235 | 1,284 | 1,355 | 1,428 | 1,524 | 1,588 | 1,655 | 1,706 | 2.00 | 1.00 | 0.00 | - | 492 |
| Cash Equivalents | 27.8% | 316 | 248 | 368 | 494 | 998 | 864 | 1,623 | 1,679 | 456 | 500 | 537 | - | 490 |
| Net PPE | -100.0% | - | 2.00 | 3.00 | 3.00 | 2.00 | 2.00 | 2.00 | 2.00 | - | - | - | - | 3.00 |
| Liabilities | 10.0% | 69.00 | 63.00 | 70.00 | 66.00 | 143 | 134 | 126 | 215 | 74.00 | 81.00 | - | 39.00 | 18.00 |
| Current Liabilities | 15.8% | 66.00 | 57.00 | 60.00 | 52.00 | 63.00 | 55.00 | 57.00 | 40.00 | 2.00 | 0.00 | 0.00 | 0.00 | 14.00 |
| Shareholder's Equity | -6.2% | 1,171 | 1,248 | 1,314 | 1,389 | 1,400 | 1,475 | 1,549 | 1,515 | 456 | 494 | 527 | 0.00 | 482 |
| Retained Earnings | -12.1% | -765 | -683 | -610 | -527 | -505 | -420 | -337 | -358 | -72.17 | -31.84 | 48.00 | -751* | -258 |
| Additional Paid-In Capital | 0.3% | 1,936 | 1,931 | 1,924 | 1,917 | 1,907 | 1,897 | 1,886 | 1,873 | - | 37.00 | 0.00 | 0.00 | 741 |
| Shares Outstanding | 0.4% | 485 | 483 | 481 | 479 | 476 | 473 | 471 | 469 | 321 | 318 | 311 | - | 298 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Quarterly) | (In Thousands) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
| Cashflow From Operations | 19.5% | -61,907 | -76,891 | -85,546 | -105,796 | -62,104 | -65,430 | -53,938 | -80,384 | -41,966 | -37,309 | -23,521 | - |
| Share Based Compensation | -28.3% | 4,869 | 6,790 | 7,592 | 9,225 | 9,432 | 9,988 | 12,906 | 22,410 | 2,016 | 1,016 | 784 | - |
| Cashflow From Investing | 394.9% | 129,874 | -44,041 | -40,359 | -398,417 | 194,916 | -693,763 | -13.00 | -4,104 | -49.00 | -252 | -43.00 | - |
| Cashflow From Financing | 182.4% | 209 | 74.00 | 127 | 327 | 774 | 361 | -1,323 | 1,306,560 | -1,673 | 345 | 71,256 | - |
EQRX Income Statement
2023-09-30CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
| Operating expenses: | ||||
| Research and development | $ 19,729 | $ 56,271 | $ 134,236 | $ 156,997 |
| General and administrative | 23,404 | 34,095 | 72,157 | 98,150 |
| Restructuring | 58,415 | 88,789 | ||
| Total operating expenses | 101,548 | 90,366 | 295,182 | 255,147 |
| Loss from operations | (101,548) | (90,366) | (295,182) | (255,147) |
| Other income (expense): | ||||
| Change in fair value of contingent earn-out liability | (110) | (2,706) | 4,556 | 90,863 |
| Change in fair value of warrant liabilities | 2,530 | (197) | 4,501 | 4,934 |
| Interest income, net | 16,485 | 8,209 | 47,995 | 12,482 |
| Other expense, net | 12 | (32) | (8) | (44) |
| Total other income (expense), net | 18,917 | 5,274 | 57,044 | 108,235 |
| Net loss | (82,631) | (85,092) | (238,138) | (146,912) |
| Other comprehensive income (loss), net of tax: | ||||
| Foreign currency translation adjustments | (14) | 33 | (3) | 49 |
| Unrealized holding gains (losses) on short-term investments | 132 | 370 | 403 | (1,672) |
| Comprehensive loss, net of tax | (82,513) | (84,689) | (237,738) | (148,535) |
| Net loss attributable to common stockholders - basic | (82,631) | (85,092) | (238,138) | (146,912) |
| Net loss attributable to common stockholders - diluted | $ (82,631) | $ (85,092) | $ (238,138) | $ (146,912) |
| Net income (loss) per share - basic (in dollars per share) | $ (0.17) | $ (0.18) | $ (0.49) | $ (0.31) |
| Net income (loss) per share - diluted (in dollars per share) | $ (0.17) | $ (0.18) | $ (0.49) | $ (0.31) |
| Weighted average common shares outstanding - basic (in shares) | 484,229,709 | 475,565,990 | 482,135,388 | 473,101,935 |
| Weighted average common shares outstanding - diluted (in shares) | 484,229,709 | 475,565,990 | 482,135,388 | 473,101,935 |
EQRX Balance Sheet
2023-09-30CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 315,676 | $ 494,136 |
| Short-term investments | 896,624 | 905,150 |
| Prepaid expenses and other current assets | 22,206 | 28,800 |
| Restricted cash | 633 | |
| Total current assets | 1,235,139 | 1,428,086 |
| Property and equipment, net | 2,627 | |
| Restricted cash | 633 | |
| Right-of-use asset | 3,804 | |
| Other investments | 4,000 | 4,000 |
| Other non-current assets | 1,151 | 15,866 |
| Total assets | 1,240,290 | 1,455,016 |
| Current liabilities: | ||
| Accounts payable | 8,103 | 19,950 |
| Accrued expenses | 55,623 | 29,596 |
| Lease liability, current | 2,060 | 2,370 |
| Total current liabilities | 65,786 | 51,916 |
| Non-current liabilities: | ||
| Contingent earn-out liability | 2,604 | 7,160 |
| Warrant liabilities | 792 | 5,293 |
| Lease liability, non-current | 1,461 | |
| Restricted stock repurchase liability | 188 | 324 |
| Total liabilities | 69,370 | 66,154 |
| Commitments and contingencies (note 13) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.0001 par value, 2,000,000 shares authorized; no shares issued and outstanding as of September 30, 2023 and December 31, 2022 | ||
| Common stock, $0.0001 par value; 1,250,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 537,540,870 and 538,549,210 shares issued as of September 30, 2023 and December 31, 2022, respectively; and 484,965,823 and 478,674,305 shares outstanding at September 30, 2023 and December 31, 2022, respectively | 49 | 49 |
| Additional paid-in capital | 1,936,346 | 1,916,550 |
| Accumulated other comprehensive income (loss) | 252 | (148) |
| Accumulated deficit | (765,727) | (527,589) |
| Total stockholders' equity | 1,170,920 | 1,388,862 |
| Total liabilities and stockholders' equity | $ 1,240,290 | $ 1,455,016 |
| Â CEO | Ms. Melanie I. Nallicheri |
|---|---|
| Â WEBSITE | www.eqrx.com |
| Â EMPLOYEES | 362 |